Project Grant R43EY037632
Award Date 9/30/25
Completion Date 9/29/26
Dollars Obligated $349K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $321,904 Project Grant to Proteris Biotech, Inc. through the Vision Research federal grant program (CFDA 93.867). The award, spanning August 1, 2025 to July 31, 2026, will fund the early development of the natural tear protein clusterin (CLU) as a novel approach to treat dry eye disease. The research aims to conduct non-GMP stability analysis of the drug substance and product, as well as perform...
- This $257,785 Project Grant was awarded on April 1, 2025 by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867). The grant supports the development of a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The key products/services to be delivered under this 4-year grant include: Characterizing and controlling the release of the...
- The National Eye Institute (NEI), under the Department of Health and Human Services, awarded a $358,065 Project Grant to Revel Pharmaceuticals Inc., a biotechnology company in San Francisco, California. The grant is part of the NEI's Vision Research program (CFDA 93.867), which supports research to understand, prevent, and treat vision-related conditions and diseases. The goal of this Phase I grant is for Revel Pharmaceuticals to optimize lead drug candidates and demonstrate the activity of...
- This Project Grant award of $492,000.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports a study on decentralized approaches to investigating evaporative dry eye disease (DED). The key products and services to be delivered under this award include: Developing a remote trial design to allow for decentralized recruitment and study of DED, including an operations manual and statistical analysis plan. Determining the feasibility and utility of obtaining transcriptomic...
- This $305,321 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the clinical development and commercialization of a topical ophthalmic treatment for neovascular age-related macular degeneration (NAMD). The funding will enable the awardee, Neovascularx, Inc., to advance their AMD101 (rifampicin) compound, which aims to provide a less invasive, home-based alternative to the current standard of care intravitreous injections for...
- The National Eye Institute (NEI) awarded a $896,046 project grant to The Schepens Eye Research Institute, Inc. in Boston, MA, under the Vision Research federal grant program (CFDA 93.867). The project, titled "Non-Invasive Electrical Stimulation as a Therapy for Diabetic Keratopathy", focuses on exploring the effectiveness of non-invasive transpalpebral electrical stimulation (TPES) as a treatment for diabetic keratopathy, a common complication in individuals with diabetes that results...
- This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides funding of $294,662 to Proteris Biotech, Inc. to support research on using the protein Clusterin (CLU) to treat ocular surface disease and dry eye. The project aims to determine whether CLU can protect the ocular surface epithelia from damage and also have an anti-inflammatory effect in dry eye disease. Recombinant human CLU will be tested for efficacy in a mouse...
- This $399,865 federal Project Grant was awarded on September 30, 2025 by the National Eye Institute (NEI), under the CFDA program "Vision Research", to Kuria Therapeutics, Inc. The grant will fund IND-enabling studies of KTX-1161, a novel topical eye drop intended to protect corneal endothelial cells during cataract surgery and treat Fuchs' endothelial corneal dystrophy. The three specific aims are to 1) conduct GLP genotoxicity studies on the active ingredient SCO-116, 2) perform...
- The National Eye Institute (NEI) awarded a $482,067 Project Grant to Washington State University (WSU) on August 1, 2025 under the Vision Research federal grant program (CFDA 93.867). The grant supports research to develop novel nanotherapies for the targeted treatment of corneal neovascularization, a sight-threatening condition characterized by the growth of blood vessels into the cornea. The funding will enable WSU researchers to synthesize a unique trehalose-based dendrimer (TRE-D) that...